Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Anlotinib + Cadonilimab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Anlotinib + Cadonilimab | Phase Ib/II | Actionable | In a Phase Ib/II trial, combination treatment with Cadonilimab and Anlotinib (AL-3818) demonstrated antitumor activity in patients with CD274 (PD-L1) positive (TPS >= 1%) non-small cell lung cancer, and led to an objective response rate of 62.5% (5/8) and a disease control rate of 100% (8/8). (Annals of Oncology 32 (2021): S1006; NCT04646330). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC | Full reference... |